論文 - 詳細
| RRC ID | 68825 |
|---|---|
| 著者 | Kono Y, Kawakami S, Higuchi Y, Maruyama K, Yamashita F, Hashida M. |
| タイトル | Antitumor effect of nuclear factor-κB decoy transfer by mannose-modified bubble lipoplex into macrophages in mouse malignant ascites. |
| ジャーナル | Cancer Sci |
| Abstract |
Patients with malignant ascites (MAs) display several symptoms, such as dyspnea, nausea, pain, and abdominal tenderness, resulting in a significant reduction in their quality of life. Tumor-associated macrophages (TAMs) play a crucial role in MA progression. Because TAMs have a tumor-promoting M2 phenotype, conversion of the M2 phenotypic function of TAMs would be promising for MA treatment. Nuclear factor-κB (NF-κB) is a master regulator of macrophage polarization. Here, we developed targeted transfer of a NF-κB decoy into TAMs by ultrasound (US)-responsive, mannose-modified liposome/NF-κB decoy complexes (Man-PEG bubble lipoplexes) in a mouse peritoneal dissemination model of Ehrlich ascites carcinoma. In addition, we investigated the effects of NF-κB decoy transfection into TAMs on MA progression and mouse survival rates. Intraperitoneal injection of Man-PEG bubble lipoplexes and US exposure transferred the NF-κB decoy into TAMs effectively. When the NF-κB decoy was delivered into TAMs by this method in the mouse peritoneal dissemination model, mRNA expression of the Th2 cytokine interleukin (IL)-10 in TAMs was decreased significantly. In contrast, mRNA levels of Th1 cytokines (IL-12, tumor necrosis factor-α, and IL-6) were increased significantly. Moreover, the expression level of vascular endothelial growth factor in ascites was suppressed significantly, and peritoneal angiogenesis showed a reduction. Furthermore, NF-κB decoy transfer into TAMs significantly decreased the ascitic volume and number of Ehrlich ascites carcinoma cells in ascites, and prolonged mouse survival. In conclusion, we transferred a NF-κB decoy efficiently by Man-PEG bubble lipoplexes with US exposure into TAMs, which may be a novel approach for MA treatment. |
| 巻・号 | 105(8) |
| ページ | 1049-55 |
| 公開日 | 2014-8-1 |
| DOI | 10.1111/cas.12452 |
| PMID | 24850474 |
| PMC | PMC4317846 |
| MeSH | Animals Carcinoma, Ehrlich Tumor* Disease Models, Animal Female Genetic Therapy / methods* Lectins, C-Type / metabolism Liposomes Macrophages / metabolism* Mannose Receptor Mannose-Binding Lectins / metabolism Mice NF-kappa B / antagonists & inhibitors Oligodeoxyribonucleotides / administration & dosage* Oligonucleotides, Antisense / administration & dosage* Real-Time Polymerase Chain Reaction Receptors, Cell Surface / metabolism Transfection / methods Ultrasonics |
| IF | 4.966 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 4 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | Ehrlich(RCB0142) |